Novartis agreed to acquire Excellergy, adding an anti-IgE antibody program (Exl-111) currently in Phase I testing. The deal broadens Novartis’ immune and inflammation pipeline, with Exl-111 positioned across multiple allergic and inflammatory indications, including food allergy and chronic spontaneous or inducible urticaria. Separately, Otsuka struck an agreement to acquire Transcend Therapeutics for $1.2 billion as it targets posttraumatic stress disorder using a neuroplastogen approach. In deals roundup coverage, the transactions were framed as part of pipeline-building activity by major pharma. For investors and developers, these deals highlight ongoing M&A emphasis on early- and mid-stage immunology assets where mechanistic fit and development speed can shift competitive positioning before pivotal data. The Excellergy acquisition also adds to a wider pattern of pharma consolidating immunology platform assets, including antibody engineering and translational clinical strategy, to sustain growth into later-cycle assets.